ABBV Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -0.15% compared to AbbVie's net margin of 23.56%. AbbVie's return on equity of 61.64% beat Gilead Sciences's return on equity of 2.5%.

AbbVie has a consensus price target of $211.73, signalling upside risk potential of 3.14%. On the other hand Gilead Sciences has an analysts' consensus of $111.71 which suggests that it could fall by -0.07%. Given that AbbVie has higher upside potential than Gilead Sciences, analysts believe AbbVie is more attractive than Gilead Sciences.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.06%. Gilead Sciences offers a yield of 2.77% to investors and pays a quarterly dividend of $0.79 per share. AbbVie pays 257.71% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $15.1B, which are larger than Gilead Sciences quarterly revenues of $7.6B. AbbVie's net income of -$22M is lower than Gilead Sciences's net income of $1.8B. Notably, AbbVie's price-to-earnings ratio is 85.54x while Gilead Sciences's PE ratio is 302.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.46x versus 4.89x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -0.15% compared to AbbVie's net margin of 15.24%. AbbVie's return on equity of 61.64% beat Johnson & Johnson's return on equity of 19.98%.

AbbVie has a consensus price target of $211.73, signalling upside risk potential of 3.14%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.27%. Given that Johnson & Johnson has higher upside potential than AbbVie, analysts believe Johnson & Johnson is more attractive than AbbVie.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.06%. Johnson & Johnson offers a yield of 3.03% to investors and pays a quarterly dividend of $1.24 per share. AbbVie pays 257.71% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AbbVie's net income of -$22M is lower than Johnson & Johnson's net income of $3.4B. Notably, AbbVie's price-to-earnings ratio is 85.54x while Johnson & Johnson's PE ratio is 28.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.46x versus 4.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -0.15% compared to AbbVie's net margin of 32.59%. AbbVie's return on equity of 61.64% beat Eli Lilly and's return on equity of 80.24%.

AbbVie has a consensus price target of $211.73, signalling upside risk potential of 3.14%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.85%. Given that Eli Lilly and has higher upside potential than AbbVie, analysts believe Eli Lilly and is more attractive than AbbVie.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.06%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. AbbVie pays 257.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are larger than Eli Lilly and quarterly revenues of $13.5B. AbbVie's net income of -$22M is lower than Eli Lilly and's net income of $4.4B. Notably, AbbVie's price-to-earnings ratio is 85.54x while Eli Lilly and's PE ratio is 70.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.46x versus 16.51x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -0.15% compared to AbbVie's net margin of 23.96%. AbbVie's return on equity of 61.64% beat Merck &'s return on equity of 40.25%.

AbbVie has a consensus price target of $211.73, signalling upside risk potential of 3.14%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 25.59%. Given that Merck & has higher upside potential than AbbVie, analysts believe Merck & is more attractive than AbbVie.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.06%. Merck & offers a yield of 3.54% to investors and pays a quarterly dividend of $0.81 per share. AbbVie pays 257.71% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are smaller than Merck & quarterly revenues of $15.6B. AbbVie's net income of -$22M is lower than Merck &'s net income of $3.7B. Notably, AbbVie's price-to-earnings ratio is 85.54x while Merck &'s PE ratio is 13.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.46x versus 3.53x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.